




# Essai Clinique

Généré le 08 févr. 2025 à partir de

Titre	A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
Protocole ID	CheckMate 74W
ClinicalTrials.gov ID	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04340193">NCT04340193</a>
Type(s) de cancer	Foie
Phase	Phase III
Type étude	Clinique
Médicament	Nivolumab et Ipilimumab, Nivolumab monothérapie ou placebo en association avec TACE
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL  L'HOTEL-DIEU DE QUEBEC ET CRCEO 11 Côte du Palais, Québec, QC, G1R 2J6
Ville	
Investigateur principal	Dr Félix Couture
Coordonnateur	Maryse Gingras 418-691-5781
Statut	Actif en recrutement
But étude	The purpose of this study is to compare effectiveness and safety of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer
Critères d'éligibilité	<ul style="list-style-type: none"><li>• Participant has intermediate-stage HCC (hepatocellular carcinoma) whose tumor characteristics exceed the BMU7 criteria and is eligible for TACE</li><li>• Participant has histologic confirmation of HCC</li><li>• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1</li><li>• Men and Women must agree to follow methods of contraception</li><li>• Participants are eligible to enroll if they have non-viral related HCC, or if they have HBV-HCC, or HCV-HCC</li></ul>
Critères d'exclusion	<ul style="list-style-type: none"><li>• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC</li><li>• Prior liver transplant or participants who are on the waiting list for liver transplantation</li><li>• Active, known, or suspected autoimmune disease</li><li>• Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications</li><li>• Any previous TACE or TAE (trans-arterial embolization without instillation of chemotherapy agent) procedure for HCC</li><li>• Known or suspected allergy to nivolumab, ipilimumab, or study drug components given in association with this trial</li></ul> <p>Other protocol defined inclusion/exclusion criteria could apply</p>